oral cancer – Page 3 – Oral Cancer News

When Is Insurance Not Really Insurance? When You Need Pricey Dental Care.

May 21, 2018 By: David Tuller Source: https://khn.org I’m 61 years old and a San Francisco homeowner with an academic position at the University of California-Berkeley, which provides me with comprehensive health insurance. Yet, to afford the more than $50,000 in out-of-pocket expenses required for the restorative dental work I’ve needed in the past 20 years, I’ve had to rely on handouts — from my mom. This was how I learned all about the Great Divide between medicine and dentistry — especially in how treatment is paid for, or mostly not paid for, by insurers. Many Americans with serious dental illness find out the same way: sticker shock. For millions of Americans — blessed in some measure with good genes and good luck — dental insurance works pretty well, and they don’t think much about it. But people like me learn the hard way that dental insurance isn’t insurance at all — not in the sense of providing significant protection against unexpected or unaffordable costs. My dental coverage from UC-Berkeley, where I have been on the public health and journalism faculties, tops out at $1,500 a year — and that’s considered a decent plan. Dental policies are more like prepayment plans for a basic level of care. They generally provide full coverage for routine preventive services and charge a small copay for fillings. But coverage is reduced as treatment intensifies. Major work like a crown or a bridge is often covered only at 50 percent; implants generally aren’t covered at all. [...]

Charlotte Parker2018-05-21T09:32:46-07:00May, 2018|Oral Cancer News|

The Sate of Liquid Biopsy

Author:Pam Harrison Date: March 5, 2018 Source: Medscape.com So called "liquid biopsies" — which can detect circulating tumor DNA (ctDNA) in blood samples — are not yet ready for prime time in the diagnosis or management of early-stage or advanced solid tumors, a new expert review concludes. These assays are also not useful, outside of clinical trials, for monitoring patients for minimal residual disease following definitive treatment of cancer, nor for cancer screening, the expert review concludes. The review was prepared jointly by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) and was published online March 5 in the Journal of Clinical Oncology. "This is an area of great interest to both pathologists and oncologists, [and] it's also an area where we see a lot of commercial advertisement and a lot of enthusiasm from the public," Jason Merker, MD, PhD, cochair of the expert panel, who was representing the CAP, said in a statement. "We thought it was a good time to look at the literature and take an evidence-based approach to various uses for ctDNA assays," he added. "Like all new things in medicine, the use of ctDNA assays in routine cancer care requires evidence of clinical utility. At present, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer, including those that interrogate a panel of genes," said Daniel F. Hayes, MD, coauthor of the review, who was representing ASCO. "What is promising is that this area [...]

Charlotte Parker2018-04-21T11:52:07-07:00March, 2018|Oral Cancer News|

Immunotherapy: beyond melanoma and lung cancer treatment

Author: David Crow Source: www.ft.com Date: March 4, 2018 In the late 1800s, William Coley, a surgeon in New York, developed what scientists now think was the first cancer immunotherapy. Coley noticed one of his patients, Fred Stein, had started recovering from cancer after catching a serious infection. The observation made him wonder whether the bacteria had somehow stimulated the patient’s immune system and recruited the body’s natural “resisting powers” in the fight against Mr. Stein’s tumours. The surgeon began treating inoperable cancer patients with bacterial injections — known as “Coley’s toxins” — and recorded some success, but his poorly documented findings were dismissed by contemporaries who favoured radiation and chemotherapy. Mr. Coley died in 1936 and his theories were all but forgotten: it would take almost 80 years for oncologists to take cancer immunotherapy seriously. Today, immunotherapies are among the world’s best selling drugs and they have dramatically improved the survival prospects for some of the sickest patients, especially those with melanoma and lung cancer. “Immunotherapy is here to stay,” says Jill O’Donnell-Tormey, chief executive of the Cancer Research Institute. “It's not just a blip, it’s not overhyped — I think it is going to become the standard of care for many cancer types.” The most common immunotherapy drugs are known as checkpoint inhibitors, which work by removing brakes in the immune system so the body can attack cancer. Their discovery was made possible by the research of James Allison, now a professor at the MD Anderson Cancer Center [...]

Charlotte Parker2018-03-05T11:28:31-07:00March, 2018|Oral Cancer News|

Suicide Among Cancer Survivors — Highest Risk in HNC

Author: Roxanne Nelson, RN, BSN Source: MedScape.com Date: Feb. 20, 2018 ORLANDO, Florida — Head and neck cancer (HNC) accounts for only about 4% of new cancer cases in the United States, but the risk for suicide among survivors is significantly higher than for survivors of all other cancer types, with the exception of pancreatic cancer. "The risk of suicide is significantly elevated across cancer sites, and the risk is especially high among HNC and pancreatic cancer survivors," said Nosayaba Osazuwa-Peters, BDS, MPH, CHES, instructor, Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, Missouri. "Cancer survivors are candidates for suicide-related psychosocial surveillance," he added. Cancer is the number 2 cause of death in the United States and accounts for 1 of every 4 deaths. Suicide is the tenth cause of death, independent of cancer. "If you add cancer to it, you get the perfect storm," he said. "Survivorship does come at a cost, and this is one of the more unfortunate costs of cancer survivorship," Osazuwa-Peters told delegates here at the Cancer Survivorship Symposium (CSS) Advancing Care and Research. Currently, there are more than 16 million survivors in the United States. The good news is that more people are surviving cancer, and there is now more focus on competing causes of death and comorbidities, he explained. There is also more focus on the increased risk for acute and late toxicities, which needs to be addressed as the rate of survival increases. Osazuwa-Peters pointed out that there [...]

Charlotte Parker2018-02-27T17:02:46-07:00February, 2018|Oral Cancer News|

Bareback Rider Cody Kiser Uses Tucson Rodeo Role to Rail Against Oral Cancer

Author: Norma Gonzalez Source: Arizona Daily Star Date: Feb. 23, 2018 Prior to Friday’s first event, Cody Kiser stretched and danced around the dressing room behind the chutes. Kiser was nothing but smiles as he loosened up for bareback riding at the 93rd annual La Fiesta de los Vaqueros. While in high school in 2006, Kiser suffered an injury competing in bull riding. The bull stepped on his face, breaking all the bones in its left side. Kiser’s jaw was broken in two places and had to be wired shut. Through plastic surgery, Kiser had his face put back together. Now, Kiser’s smile is more than just a gruesome injury story. The 27-year-old from Carson City became a spokesperson and role model with the Oral Cancer Foundation in 2014, and is the first spokesman to be affiliated with the rodeo. “My side of it isn’t giving out a lot of facts,” he said. “Everyone knows smoking and chewing is bad. If you do it long enough, it’ll kill you.” Kiser has never smoked or chewed. He simply doesn’t like it. “I was never part of that,” Kiser said. “I just like to lead a healthy lifestyle and it just worked out so perfect to get involved with the foundation.” So now, the bareback rider lends his voice to the foundation and helps in the prevention of tobacco use. According to oralcancer.org, as many as 15 percent of high school boys use smokeless tobacco in the United States. The nicotine content in [...]

Charlotte Parker2018-02-27T10:35:38-07:00February, 2018|Oral Cancer News|

New cancer test isn’t ready for prime time

Author: H Gilbert Welch Date: February 14, 2018 Source: http://www.cnn.com/2018/02/13/opinions/liquid-biopsy-opinion-welch/index.html (CNN)- A simple blood test to detect cancer early. How great is that? There has been enthusiasm about the so-called "liquid biopsy" for years. In mid-January, however, doctors learned more -- both about this vision and its problems. A widely reported study in the journal Science described a liquid biopsy test -- CancerSEEK -- which combined measuring eight tumor biomarkers with testing for pieces of DNA with cancer associated mutations in 16 genes. It's not one test; it's a battery of tests. And while collecting the blood may be simple, the subsequent analysis is extraordinarily complex. The task at hand is particularly challenging. We all have pieces of DNA in our blood. Distinguishing the tumor DNA from the background DNA requires finding the mutations specifically associated with cancer. Adding to the complexity, healthy individuals can have mutations. To avoid labeling innocuous mutations as cancerous requires a bunch of statistical fine-tuning. In other words, there are a lot of steps in a liquid biopsy and much potential for things to go awry. To their credit, the CancerSEEK investigators were very forthright that the study conditions were ideal for the test to accurately detect cancer. The liquid biopsy simply had to discriminate between patients with known cancer (the majority of whom had symptoms) and healthy individuals. And the statistical fine-tuning was tailored to the study participants -- with the knowledge of who had, and who did not have, cancer. Although the test was [...]

Charlotte Parker2018-02-14T11:36:19-07:00February, 2018|Oral Cancer News|

CDHA Urges Hygienists to Remind Patients of Oral Cancer Screening

Author: Canadian Dental Hygienists Association Date: January 29, 2018 Source: https://www.oralhealthgroup.com World Cancer Day (February 4) is a perfect time for dental hygienists across Canada to remind the public of the importance of regular oral cancer screenings, not only during dental appointments, but also now at home. The Canadian Cancer Society projected in 2017 that 4,700 Canadians would be diagnosed with oral cavity cancer, and that 1,250 Canadians would die. In hopes of improving the long-term outcomes for people diagnosed with oral cancer, the Canadian Dental Hygienists Association (CDHA) has partnered with the Oral Cancer Foundation and the American Dental Hygienists Association on a “Check Your Mouth™” initiative to help individuals identify the early signs and symptoms of oral cavity cancers. “Dental hygienists recognize that early detection has great potential to reduce the oral cancer burden in Canada,” states Sophia Baltzis, CDHA president. “Between dental visits, which usually include an oral cancer screening, our clients can and should examine their mouths for suspicious tissue changes.” The Check Your Mouth™ campaign features an interactive website (www.checkyourmouth.org) that offers easy-to-use tools and tips for a quick visual and tactile examination of the oral cavity. Individuals can learn to self-discover the early symptoms of disease and then seek further evaluation from a dental professional if necessary. “Dental hygienists are your partners in prevention,” adds Baltzis. “We encourage all Canadians to maintain a healthy lifestyle, practice good oral hygiene habits, and spot the early signs of oral cancer. The Check Your Mouth™ website is a valuable [...]

Charlotte Parker2018-02-06T14:57:40-07:00January, 2018|Oral Cancer News|

Study Identifies Potential Cause of Hearing Loss from Cisplatin

Author: NCI Staff Date: January 26, 2018 Source: National Cancer Institute (https://www.cancer.gov/news-events) Results from a new study may explain why many patients treated with the chemotherapy drug cisplatin develop lasting hearing loss. Researchers found that, in both mice and humans, cisplatin can be found in the cochlea—the part of the inner ear that enables hearing—months and even years after treatment. By contrast, the drug is eliminated from most organs in the body within days to weeks after being administered. The study, led by researchers from the National Institute on Deafness and other Communication Disorders (NIDCD), part of the National Institutes of Health, was published November 21 in Nature Communications. Cisplatin, a platinum-based chemotherapy drug, is commonly used for the treatment of many cancers, including bladder, ovarian, and testicular cancers. But cisplatin and other similar platinum-containing drugs can damage the cochlea, leaving 40%–80% of adults, and at least 50% of children, with significant permanent hearing loss, a condition that can greatly affect quality of life. “This study starts to explain why patients who receive the drug sustain hearing loss,” said Percy Ivy, M.D., associate chief of NCI’s Investigational Drug Branch, who was not involved in the study. “This is very important, because as we come to understand how cisplatin-related hearing loss occurs, over time we may figure out a way to block it, or at least diminish its effects.” A New Approach to Researching Cisplatin-Induced Hearing Loss The new study differs from previous research because it is a comprehensive look at the pharmacokinetics, or concentration, of the [...]

Charlotte Parker2018-02-06T14:57:52-07:00January, 2018|Oral Cancer News|

Anti-smoking plan may kill cigarettes–and save Big Tobacco

Date: January 19, 2018 Author: Matthew Perrone Source: www.apnews.com WASHINGTON (AP) — Imagine if cigarettes were no longer addictive and smoking itself became almost obsolete; only a tiny segment of Americans still lit up. That’s the goal of an unprecedented anti-smoking plan being carefully fashioned by U.S. health officials. But the proposal from the Food and Drug Administration could have another unexpected effect: opening the door for companies to sell a new generation of alternative tobacco products, allowing the industry to survive — even thrive — for generations to come. The plan puts the FDA at the center of a long-standing debate over so-called “reduced-risk” products, such as e-cigarettes, and whether they should have a role in anti-smoking efforts, which have long focused exclusively on getting smokers to quit. “This is the single most controversial — and frankly, divisive — issue I’ve seen in my 40 years studying tobacco control policy,” said Kenneth Warner, professor emeritus at University of Michigan’s school of public health. The FDA plan is two-fold: drastically cut nicotine levels in cigarettes so that they are essentially non-addictive. For those who can’t or won’t quit, allow lower-risk products that deliver nicotine without the deadly effects of traditional cigarettes. US health officials are pushing ahead with an unprecedented plan to make cigarettes less addictive and provide lower-risk alternative products to US smokers. (Jan. 19) This month the government effort is poised to take off. The FDA is expected to soon begin what will likely be a years-long process [...]

Charlotte Parker2018-02-06T14:58:15-07:00January, 2018|Oral Cancer News|

HPV vaccine is safe, effective after 10 years: study

Author: AFP/RelaxNews Date: November 30, 2017 Source: Globalnews.ca New research looking into the long-term effects of the human papillomavirus (HPV) vaccine has found it to be both safe and effective in protecting against the most virulent strains of the virus. Led by Dr. Daron G. Ferris, professor in the Department of Obstetrics and Gynecology at the Medical College of Georgia and at the Georgia Cancer Center at Augusta University, the study is the longest followup to date on the vaccine, looking at data from 1,661 male and female participants who were followed for just under 10 years. Of these participants, around two-thirds received a three-dose regimen of the vaccine when they were ages nine to 15 and sexually inactive. Initially about one-third received a placebo — not a vaccine — however, the placebo group also received the vaccine 30 months into the study, meaning that these individuals were followed a shorter period of time. Ferris found that the vaccine was virtually 100 per cent effective in preventing the disease, although vaccinating earlier produced the most robust initial and long-term antibody response, the proteins found in the blood which help fight infection. “We needed to answer questions like if we vaccinate earlier in life, will it last,” explained Ferris, “The answer is yes, this cancer prevention vaccine is working incredibly well 10 years later. A booster vaccine likely will not be needed by these young people. I think now we have come full circle.” The new finding also supports previous research which suggests that [...]

Charlotte Parker2017-12-03T14:03:35-07:00November, 2017|Oral Cancer News|